Review



polyclonal rabbit antihuman sgo2 antibody  (Atlas Antibodies)


Bioz Verified Symbol Atlas Antibodies is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Atlas Antibodies polyclonal rabbit antihuman sgo2 antibody
    Figure 2. The expression level of <t>SGO2</t> is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) (a), TCGA (b), and CGGA (c). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10–11 by log- rank test, 95% CI 2.13–4.25, hazard ratio 3.01).
    Polyclonal Rabbit Antihuman Sgo2 Antibody, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit antihuman sgo2 antibody/product/Atlas Antibodies
    Average 92 stars, based on 4 article reviews
    polyclonal rabbit antihuman sgo2 antibody - by Bioz Stars, 2026-02
    92/100 stars

    Images

    1) Product Images from "Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas."

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    Journal: Scientific reports

    doi: 10.1038/s41598-021-97119-4

    Figure 2. The expression level of SGO2 is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) (a), TCGA (b), and CGGA (c). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10–11 by log- rank test, 95% CI 2.13–4.25, hazard ratio 3.01).
    Figure Legend Snippet: Figure 2. The expression level of SGO2 is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) (a), TCGA (b), and CGGA (c). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10–11 by log- rank test, 95% CI 2.13–4.25, hazard ratio 3.01).

    Techniques Used: Expressing

    Figure 1. The expression level of SGO2 is related to pathological grading of gliomas. The SGO2 mRNA level in different grade of gliomas and non-tumor brain tissue from GEO profile (GDS1962/230165_at/SGO2) (a), TCGA (b), and CCGA (c). SGO2 expression was significantly higher in high-grade gliomas (Grade III and IV) than in low-grade gliomas (Grade II) and non-tumor control. The Y-axis indicates the SGO2 mRNA expression. The p value was adjusted by Bonferroni method in R software (version 3.0.1) between each group.
    Figure Legend Snippet: Figure 1. The expression level of SGO2 is related to pathological grading of gliomas. The SGO2 mRNA level in different grade of gliomas and non-tumor brain tissue from GEO profile (GDS1962/230165_at/SGO2) (a), TCGA (b), and CCGA (c). SGO2 expression was significantly higher in high-grade gliomas (Grade III and IV) than in low-grade gliomas (Grade II) and non-tumor control. The Y-axis indicates the SGO2 mRNA expression. The p value was adjusted by Bonferroni method in R software (version 3.0.1) between each group.

    Techniques Used: Expressing, Control, Software

    Figure 4. Validation of SGO2 protein expression in human gliomas and non-tumor brain tissue. Hematoxylin and eosin staining of non-tumor brain tissue (a), low grade (b) and high grade gliomas (c). The immunohistochemical staining of SGO2 on non-tumor brain tissue (d), low grade (e), and high grade gliomas (f) (scale bar: 50 μm). (g–i) The SGO2 immunostaining scores in normal brain tissue, low-grade glioma and high-grade glioma were statistically analyzed. The adjusted p value was calibrated between each group.
    Figure Legend Snippet: Figure 4. Validation of SGO2 protein expression in human gliomas and non-tumor brain tissue. Hematoxylin and eosin staining of non-tumor brain tissue (a), low grade (b) and high grade gliomas (c). The immunohistochemical staining of SGO2 on non-tumor brain tissue (d), low grade (e), and high grade gliomas (f) (scale bar: 50 μm). (g–i) The SGO2 immunostaining scores in normal brain tissue, low-grade glioma and high-grade glioma were statistically analyzed. The adjusted p value was calibrated between each group.

    Techniques Used: Biomarker Discovery, Expressing, Staining, Immunohistochemical staining, Immunostaining

    Figure 3. Validation of SGO2 mRNA and protein levels in glioma cell lines and normal brain tissue (a) qRT- PCR was performed to examine SGO2 mRNA expression and the quantitative results are shown in glioma cell lines. The relative expressions were normalized with normal brain. Bars mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) Protein lysates of glioma cell lines, including U87MG, LN229, GBM8401, and U118MG were applied to SDS-PAGE and Western blot analysis to quantitate SGO2 protein expression (full length blot is presented in Supplementary Fig. 1). GAPDH served as a loading control.
    Figure Legend Snippet: Figure 3. Validation of SGO2 mRNA and protein levels in glioma cell lines and normal brain tissue (a) qRT- PCR was performed to examine SGO2 mRNA expression and the quantitative results are shown in glioma cell lines. The relative expressions were normalized with normal brain. Bars mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) Protein lysates of glioma cell lines, including U87MG, LN229, GBM8401, and U118MG were applied to SDS-PAGE and Western blot analysis to quantitate SGO2 protein expression (full length blot is presented in Supplementary Fig. 1). GAPDH served as a loading control.

    Techniques Used: Biomarker Discovery, Quantitative RT-PCR, Expressing, SDS Page, Western Blot, Control

    Figure 5. The effect of SGO2 on cell proliferation and apoptosis (a) The SGO2 knockdown model constructed by siRNA 25 nM transfection into LN229 and GBM8401 cell lines. The knockdown efficiency of SGO2 siRNA or control siRNA in infected LN229 and GBM8401 cells measured by RT-qPCR. Bars, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) LN229 and GBM8401 cells were transfected with 25 nM siRNA or siControl. Cell count was determined at the indicated time points. The data are expressed as the mean ± s.d.; n = 3; **p < 0.01, and ***p < 0.001. (c) LN229 and GBM8401 cell with siSGO2 or siControl transfection were labeled with BrdU then proceeded analysis by flow cytometry (**p < 0.01, ***p < 0.005). (d) Cell cycle analysis of LN229 and GBM8401 siSGO2 cells was determined by propidium iodide (PI) stain and flow cytometry. The data are expressed as the mean ± s.d.; n = 3; *p < 0.05, **p < 0.01. (e) Cell apoptosis analysis of LN 229 and GBM8401 siSGO2 cells were determined by tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye and flow cytometry.
    Figure Legend Snippet: Figure 5. The effect of SGO2 on cell proliferation and apoptosis (a) The SGO2 knockdown model constructed by siRNA 25 nM transfection into LN229 and GBM8401 cell lines. The knockdown efficiency of SGO2 siRNA or control siRNA in infected LN229 and GBM8401 cells measured by RT-qPCR. Bars, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) LN229 and GBM8401 cells were transfected with 25 nM siRNA or siControl. Cell count was determined at the indicated time points. The data are expressed as the mean ± s.d.; n = 3; **p < 0.01, and ***p < 0.001. (c) LN229 and GBM8401 cell with siSGO2 or siControl transfection were labeled with BrdU then proceeded analysis by flow cytometry (**p < 0.01, ***p < 0.005). (d) Cell cycle analysis of LN229 and GBM8401 siSGO2 cells was determined by propidium iodide (PI) stain and flow cytometry. The data are expressed as the mean ± s.d.; n = 3; *p < 0.05, **p < 0.01. (e) Cell apoptosis analysis of LN 229 and GBM8401 siSGO2 cells were determined by tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye and flow cytometry.

    Techniques Used: Knockdown, Construct, Transfection, Control, Infection, Quantitative RT-PCR, Cell Counting, Labeling, Flow Cytometry, Cell Cycle Assay, Staining

    Figure 6. The effect of SGO2 knockdown on cell migration detected by wound-healing assays. Images and Quantitative analysis of LN229 (a) and GBM8401 (b) cells in the wound-healing assay. Data are presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01.
    Figure Legend Snippet: Figure 6. The effect of SGO2 knockdown on cell migration detected by wound-healing assays. Images and Quantitative analysis of LN229 (a) and GBM8401 (b) cells in the wound-healing assay. Data are presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01.

    Techniques Used: Knockdown, Migration, Wound Healing Assay

    Figure 7. The SGO2 protein–protein interaction (PPI) network. (a) In the PPI network established by STRING dataset, SGO2 is a hub protein. (b) The STRING dataset also predicted the association between SGO2, ARUKB, and FOXM1. (c) Protein lysates of LN229 and GBM8401 were applied to SDS-PAGE and Western blot to investigate the protein expression of AURKB and FOXM1(full length blot is presented in Supplementary Fig. 2). α-actinin served as a loading control.
    Figure Legend Snippet: Figure 7. The SGO2 protein–protein interaction (PPI) network. (a) In the PPI network established by STRING dataset, SGO2 is a hub protein. (b) The STRING dataset also predicted the association between SGO2, ARUKB, and FOXM1. (c) Protein lysates of LN229 and GBM8401 were applied to SDS-PAGE and Western blot to investigate the protein expression of AURKB and FOXM1(full length blot is presented in Supplementary Fig. 2). α-actinin served as a loading control.

    Techniques Used: SDS Page, Western Blot, Expressing, Control



    Similar Products

    polyclonal rabbit antihuman sgo2 antibody  (Atlas Antibodies)
    92
    Atlas Antibodies polyclonal rabbit antihuman sgo2 antibody
    Figure 2. The expression level of <t>SGO2</t> is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) (a), TCGA (b), and CGGA (c). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10–11 by log- rank test, 95% CI 2.13–4.25, hazard ratio 3.01).
    Polyclonal Rabbit Antihuman Sgo2 Antibody, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal rabbit antihuman sgo2 antibody/product/Atlas Antibodies
    Average 92 stars, based on 1 article reviews
    polyclonal rabbit antihuman sgo2 antibody - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2. The expression level of SGO2 is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) (a), TCGA (b), and CGGA (c). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10–11 by log- rank test, 95% CI 2.13–4.25, hazard ratio 3.01).

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 2. The expression level of SGO2 is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) (a), TCGA (b), and CGGA (c). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10–15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10–11 by log- rank test, 95% CI 2.13–4.25, hazard ratio 3.01).

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: Expressing

    Figure 1. The expression level of SGO2 is related to pathological grading of gliomas. The SGO2 mRNA level in different grade of gliomas and non-tumor brain tissue from GEO profile (GDS1962/230165_at/SGO2) (a), TCGA (b), and CCGA (c). SGO2 expression was significantly higher in high-grade gliomas (Grade III and IV) than in low-grade gliomas (Grade II) and non-tumor control. The Y-axis indicates the SGO2 mRNA expression. The p value was adjusted by Bonferroni method in R software (version 3.0.1) between each group.

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 1. The expression level of SGO2 is related to pathological grading of gliomas. The SGO2 mRNA level in different grade of gliomas and non-tumor brain tissue from GEO profile (GDS1962/230165_at/SGO2) (a), TCGA (b), and CCGA (c). SGO2 expression was significantly higher in high-grade gliomas (Grade III and IV) than in low-grade gliomas (Grade II) and non-tumor control. The Y-axis indicates the SGO2 mRNA expression. The p value was adjusted by Bonferroni method in R software (version 3.0.1) between each group.

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: Expressing, Control, Software

    Figure 4. Validation of SGO2 protein expression in human gliomas and non-tumor brain tissue. Hematoxylin and eosin staining of non-tumor brain tissue (a), low grade (b) and high grade gliomas (c). The immunohistochemical staining of SGO2 on non-tumor brain tissue (d), low grade (e), and high grade gliomas (f) (scale bar: 50 μm). (g–i) The SGO2 immunostaining scores in normal brain tissue, low-grade glioma and high-grade glioma were statistically analyzed. The adjusted p value was calibrated between each group.

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 4. Validation of SGO2 protein expression in human gliomas and non-tumor brain tissue. Hematoxylin and eosin staining of non-tumor brain tissue (a), low grade (b) and high grade gliomas (c). The immunohistochemical staining of SGO2 on non-tumor brain tissue (d), low grade (e), and high grade gliomas (f) (scale bar: 50 μm). (g–i) The SGO2 immunostaining scores in normal brain tissue, low-grade glioma and high-grade glioma were statistically analyzed. The adjusted p value was calibrated between each group.

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: Biomarker Discovery, Expressing, Staining, Immunohistochemical staining, Immunostaining

    Figure 3. Validation of SGO2 mRNA and protein levels in glioma cell lines and normal brain tissue (a) qRT- PCR was performed to examine SGO2 mRNA expression and the quantitative results are shown in glioma cell lines. The relative expressions were normalized with normal brain. Bars mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) Protein lysates of glioma cell lines, including U87MG, LN229, GBM8401, and U118MG were applied to SDS-PAGE and Western blot analysis to quantitate SGO2 protein expression (full length blot is presented in Supplementary Fig. 1). GAPDH served as a loading control.

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 3. Validation of SGO2 mRNA and protein levels in glioma cell lines and normal brain tissue (a) qRT- PCR was performed to examine SGO2 mRNA expression and the quantitative results are shown in glioma cell lines. The relative expressions were normalized with normal brain. Bars mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) Protein lysates of glioma cell lines, including U87MG, LN229, GBM8401, and U118MG were applied to SDS-PAGE and Western blot analysis to quantitate SGO2 protein expression (full length blot is presented in Supplementary Fig. 1). GAPDH served as a loading control.

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: Biomarker Discovery, Quantitative RT-PCR, Expressing, SDS Page, Western Blot, Control

    Figure 5. The effect of SGO2 on cell proliferation and apoptosis (a) The SGO2 knockdown model constructed by siRNA 25 nM transfection into LN229 and GBM8401 cell lines. The knockdown efficiency of SGO2 siRNA or control siRNA in infected LN229 and GBM8401 cells measured by RT-qPCR. Bars, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) LN229 and GBM8401 cells were transfected with 25 nM siRNA or siControl. Cell count was determined at the indicated time points. The data are expressed as the mean ± s.d.; n = 3; **p < 0.01, and ***p < 0.001. (c) LN229 and GBM8401 cell with siSGO2 or siControl transfection were labeled with BrdU then proceeded analysis by flow cytometry (**p < 0.01, ***p < 0.005). (d) Cell cycle analysis of LN229 and GBM8401 siSGO2 cells was determined by propidium iodide (PI) stain and flow cytometry. The data are expressed as the mean ± s.d.; n = 3; *p < 0.05, **p < 0.01. (e) Cell apoptosis analysis of LN 229 and GBM8401 siSGO2 cells were determined by tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye and flow cytometry.

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 5. The effect of SGO2 on cell proliferation and apoptosis (a) The SGO2 knockdown model constructed by siRNA 25 nM transfection into LN229 and GBM8401 cell lines. The knockdown efficiency of SGO2 siRNA or control siRNA in infected LN229 and GBM8401 cells measured by RT-qPCR. Bars, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.005 showed significant differences. Data are representative of three independent experiments. (b) LN229 and GBM8401 cells were transfected with 25 nM siRNA or siControl. Cell count was determined at the indicated time points. The data are expressed as the mean ± s.d.; n = 3; **p < 0.01, and ***p < 0.001. (c) LN229 and GBM8401 cell with siSGO2 or siControl transfection were labeled with BrdU then proceeded analysis by flow cytometry (**p < 0.01, ***p < 0.005). (d) Cell cycle analysis of LN229 and GBM8401 siSGO2 cells was determined by propidium iodide (PI) stain and flow cytometry. The data are expressed as the mean ± s.d.; n = 3; *p < 0.05, **p < 0.01. (e) Cell apoptosis analysis of LN 229 and GBM8401 siSGO2 cells were determined by tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye and flow cytometry.

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: Knockdown, Construct, Transfection, Control, Infection, Quantitative RT-PCR, Cell Counting, Labeling, Flow Cytometry, Cell Cycle Assay, Staining

    Figure 6. The effect of SGO2 knockdown on cell migration detected by wound-healing assays. Images and Quantitative analysis of LN229 (a) and GBM8401 (b) cells in the wound-healing assay. Data are presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01.

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 6. The effect of SGO2 knockdown on cell migration detected by wound-healing assays. Images and Quantitative analysis of LN229 (a) and GBM8401 (b) cells in the wound-healing assay. Data are presented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01.

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: Knockdown, Migration, Wound Healing Assay

    Figure 7. The SGO2 protein–protein interaction (PPI) network. (a) In the PPI network established by STRING dataset, SGO2 is a hub protein. (b) The STRING dataset also predicted the association between SGO2, ARUKB, and FOXM1. (c) Protein lysates of LN229 and GBM8401 were applied to SDS-PAGE and Western blot to investigate the protein expression of AURKB and FOXM1(full length blot is presented in Supplementary Fig. 2). α-actinin served as a loading control.

    Journal: Scientific reports

    Article Title: Shugosin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas.

    doi: 10.1038/s41598-021-97119-4

    Figure Lengend Snippet: Figure 7. The SGO2 protein–protein interaction (PPI) network. (a) In the PPI network established by STRING dataset, SGO2 is a hub protein. (b) The STRING dataset also predicted the association between SGO2, ARUKB, and FOXM1. (c) Protein lysates of LN229 and GBM8401 were applied to SDS-PAGE and Western blot to investigate the protein expression of AURKB and FOXM1(full length blot is presented in Supplementary Fig. 2). α-actinin served as a loading control.

    Article Snippet: The tissue microarrays were incubated with a polyclonal rabbit antihuman SGO2 antibody (HPA035163, Atlas Antibodies, Stockholm.

    Techniques: SDS Page, Western Blot, Expressing, Control